|
|
|
| Effect of Zoledronic Acid Injection on Bone Pain Score and Bone Metabolism Index in Patients with Osteoporosis |
| LIU Hailong, WANG Zhigang, GONG Jian |
| Tieling Central Hospital, Liaoning Tieling112000, China |
|
|
|
|
Abstract Objective: To study the role of zoledronic acid in the treatment of osteoporosis and to explore its effect on bone metabolism. Methods: One hundred and sixty patients diagnosed as primary osteoporosis in our hospital from January 2017 to March 2019 were randomly divided into treatment group (80 cases) and control group (80 cases). Patients in the control group were giving oral Calcium D tablets daily for 12 months. Patients in the treatment group were given intravenous zoledronic acid (Zometa). ANOVA with repeated measurement data was used to compare the pain scores, bone mineral density and bone metabolism related indexes of the two groups of patients before and one year after treatment. Results: The differences in bone pain scores, bone mineral density, and other bone metabolism indexes between the two groups were statistically significant (P<0.001), and the differences before and after treatment were statistically significant (P<0.001). There is an interaction effect between the groups and time (P<0.001). The differences between the two groups before and after treatment were different, and the treatment group has a larger change (P<0.001). There was no statistically significant difference in blood calcium (Ca), blood phosphorus (P), and BGP levels between the two groups of patients, nor was the difference between before and after treatment, and there was no interaction; the difference in BALP between the two groups was statistically significant ( P<0.001), the differences in BALP levels before and after treatment were statistically significant (P<0.001), and there was an interaction between different groups and time (P<0.001), and the differences between the two groups before and after treatment were different. The group changed more significantly (P<0.001). The incidence of the control group was 7.50%, and the incidence of the treatment group was 8.75%. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: Zoledronic acid can effectively improve bone pain and bone metabolism related indicators, reduce bone resorption, increase bone density, less adverse reactions, and better patient compliance.
|
|
|
|
|
|
[1] 浦祥玲,黄辰羊,张悠扬,等.绝经后骨质疏松静滴唑来膦酸急性期发热相关因素分析[J].中国骨质疏松杂志,2018,24(10):1273~1277,1316.
[2] 潘信达,宁斌,王晓鹏,等.唑来膦酸抗骨质疏松治疗对于PKP术后再发邻近椎体压缩性骨折的影响[J].潍坊医学院学报,2020,42(2):153~155.
[3] 尹自龙,石磊,张啓维,等.唑来膦酸对颈椎前路椎间盘切除椎间融合术后的疗效观察[J].中国临床医生杂志,2020,48(4):462~466.
[4] 周影,潘卫民,孙雯,等.唑来膦酸及云克治疗骨质疏松症的疗效对比研究[J].海南医学院学报,2020,26(16):1237~1241,1249.
[5] 任华,张之梁,蔡伟,等.唑来膦酸联合碳酸钙D3治疗糖尿病性骨质疏松症的疗效及其对患者骨密度和骨代谢指标的影响[J].河北医学,2020,26(1):45~50.
[6] 沈坚英,朱红娅,寿张轩,等.老年女性骨质疏松症患者静脉滴注唑来膦酸后24个月内骨转换标志物的变化[J].中国医药,2020,15(1):96~99. |
|
|
|
2021, Vol. 27 
